# OnCo record irae-hepatitis (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/irae-hepatitis/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "irae-hepatitis" ;
  schema:name "Immune-mediated hepatitis from checkpoint inhibitors, by grade"@en ;
  schema:alternateName "checkpoint inhibitor hepatitis"@en, "ICI hepatotoxicity"@en, "immune-related hepatitis"@en, "IMH"@en, "immunotherapy liver inflammation"@en ;
  schema:description "Immunotherapy can inflame the liver, usually without symptoms, so liver blood tests are checked before every dose. If the tests rise, immunotherapy is paused and steroids are given; severe cases mean stopping immunotherapy. Yellow skin or eyes, dark urine or pale stools need a call to your cancer team the same day."@en ;
  schema:url <https://onco.cc/protocols/irae-hepatitis/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "irae", "acute-oncology" ;
  onco:related <https://onco.cc/protocols/irae-colitis/>, <https://onco.cc/protocols/irae-pneumonitis/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/methylprednisolone/> ;
  onco:institutions <https://onco.cc/institutions/sitc/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/irae/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/> .